June 12−15, 2026, Istanbul, Türkiye

European Academy of Allergy and Clinical Immunology (EAACI)

Poster icon

Remibrutinib-induced decreases in B cell biomarkers are associated with complete and sustained response in chronic spontaneous urticaria patients

M. Metz, S. Saini, M. Hide, T. Rodosthenous, A. Avrameas, C.H. Kollenda-Strunk, A.S. Lindemann, A.L. Kilian, P. Budde, M. Bräutigam, H.D. Zucht, B. Cenni, U. Gehrmann, N. Chapman-Rothe, S. Haemmerle
Abstract Flash Talk
Poster icon

REASSERT: A global, prospective, non-interventional, patient-centric study evaluating the effectiveness and safety of remibrutinib and quality of life (QoL) in patients with chronic spontaneous urticaria (CSU)

M. Metz, S. Saini, Z. Zhao, K. Hayama, A. Armstrong, A. Fukunaga, I. Khan, T. Raftery, N. Chapman-Rothe, A.M. Giménez-Arnau
Abstract Flash Talk
Poster icon

Implementation of a urticaria care package in the general practitioner setting increased quality of chronic spontaneous urticaria management

E. Iemoli, P. Calzavara-Pinton, P. Saraswat, N. Chapman-Rothe, V. Nallasamy, A. Herbst, B. Gaglio, F. Speranza, O. Bonavita, T. Raftery, R. Asero
Abstract Flash Talk
Poster icon

Unmet needs in treatment escalation for chronic spontaneous urticaria: Findings from the CURE Registry

P. Kolkhir, P. Salameh, M. Zajac, A. Kasperska-Zajac, A.M. Giménez Arnau, M. Puertolas, H. Bonnekoh, C. Vera Ayala, M. Makris, E. Chatzidimitriou, S. Gregoriou, K. Kulthanan, A. Bauer, M. Bizjak Suran, D. Fomina, A. Bocquet, J. Dissemond, M. Abuzakouk, T. Raftery, N. Chapman-Rothe, E. Kocatürk, C. Grattan, R. Asero, J.G. Peter, S.F. Thomsen, K. Weller
Abstract Flash Talk
Poster icon

Urticaria Voices: Patient-reported disease burden and treatment experiences in Chronic Spontaneous Urticaria in China - A real-world evidence study (UV in China)

B. Yang, L. Yi, T. Raftery, N. Chapman-Rothe, P. Saraswat, J. McCarthy, R.K. Kohli, C. Constantinescu, A. Li, G. You, R. Tan, Z. Zhao
Abstract Thematic Poster Session
Poster icon

Urticaria Voices: Physician-reported perspectives of chronic urticaria care and its treatment in China (UV in China)

Z. Zhao, L. Yi, T. Raftery, N. Chapman-Rothe, P. Saraswat, J. McCarthy, R. Kaur Kohli, P. Orfanos, C. Constantinescu, A. Li, G. You, R. Tan, B. Yang
Abstract Thematic Poster Session
Poster icon

Dose-response analysis of remibrutinib in oral food challenge outcomes among adults with IgE-mediated peanut allergy

R.A. Wood, R. Tan, B. Cenni, R. Huang, J. Dunlop, H.C. Tillmann, T. Severin, A. Gautier, J.G. Mena, M. Ligueros-Saylan, B. Ortiz, D.F. Soteres
Abstract Thematic Poster Session
Poster icon

Efficacy and safety of remibrutinib in adults with IgE-mediated peanut allergy: A Phase 2 study

R.A. Wood, R. Tan, B. Cenni, R. Huang, J. Dunlop, M. Garcia, L. Taylor, M. Ligueros-Saylan, B. Ortiz, T. Severin, D.F. Soteres
Abstract Thematic Poster Session
Poster icon

Remibrutinib demonstrated continuous efficacy and favorable safety in patients with chronic spontaneous urticaria in the randomized withdrawal period of the phase 3b REMIXED extension study

M. Metz, A.M. Giménez-Arnau, M. Hide, M. Lebwohl, G. Mosnaim, V. Jain, K. Hayama, U. Lippert, M. Palumbo, B. Yang, K. Kulthanan, Y.M. Ye, S. Dahale, S. Haemmerle, L. Jaskiewicz, K. Lheritier, C. Field, L. Wei, S. Saini
Abstract Oral Abstract Session
Poster icon

Remibrutinib demonstrated superior efficacy vs placebo and favorable safety in patients with chronic inducible urticaria in the phase 3 REMIND study

G. Mosnaim, A.M. Giménez-Arnau, L.F. Ensina, S.M. Ferrucci, L. Finklea, A. Fukunaga, K. Hayama, M. Hide, J.S. Kern, P.H. Li, J. Reed, H. Rockmann, S. Saini, P. Staubach, J. Xu, B. Yang, A. Burciu, L. Chen, C. Field, S. Haemmerle, K. Lheritier, M. Porter, M. Metz
Abstract Oral Abstract Session
Novartis logo
FA-11248855-1     08/26
Cookie Settings
© Copyright 2026 Novartis Pharma AG